AGVHD
Clinical trials for AGVHD explained in plain language.
Never miss a new study
Get alerted when new AGVHD trials appear
Sign up with your email to follow new studies for AGVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to stop deadly transplant complication
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…
Matched conditions: AGVHD
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug cocktail aims to tame transplant complication
Disease control Not yet recruitingThis phase 2 trial tests a combination of Gecacitinib (a pill) and a corticosteroid as the first treatment for grade II to IV acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The study will enroll 25 adults who have recently received a…
Matched conditions: AGVHD
Phase: PHASE2 • Sponsor: Bin Gu • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC